Botulinum toxin A injection to the external urethral sphincter for voiding dysfunction in females: A tertiary center experience.
nonrelaxing sphincter
ona-botulinum toxin A
urethral pressure profile
videourodynamic
voiding dysfunction
Journal
Neurourology and urodynamics
ISSN: 1520-6777
Titre abrégé: Neurourol Urodyn
Pays: United States
ID NLM: 8303326
Informations de publication
Date de publication:
11 2022
11 2022
Historique:
revised:
10
07
2022
received:
12
02
2022
accepted:
21
07
2022
pubmed:
19
8
2022
medline:
2
11
2022
entrez:
18
8
2022
Statut:
ppublish
Résumé
The aim of this study is to examine the functional outcomes of ona-botulinum toxin A (BTX-A) injection into the external urethral sphincter (EUS) for female patients with nonneurogenic nonrelaxing sphincter as the underlying cause of voiding dysfunction (VD). A retrospective analysis was performed for all the patients with the urodynamic findings of higher than expected maximum urethral closure pressure (MUCP) who received their first injection during the study period. All patients were evaluated with preoperative videourodynamic study and urethral pressure profilometry and received 100 U of EUS BTX-A. Patients aged less than 18 years and those with neurogenic bladder were excluded. All patients were followed up with the free flow, postvoid residuals (PVR), and patient global impression of improvement (PGI-I) scale at 6 weeks and then at 3 monthly intervals. We identified 35 female patients with a mean age of 37.5 ± 15 years (range 18-72 years) with a mean follow-up of 20 months. More than 50% of patients had a history of prior surgical intervention and 28 (80%) patients were catheter dependent, a suprapubic catheterization, or clean intermittent self-catheterization. Mean MUCP was 97.1 ± 22 cm of water. After treatment with BTX-A, 21 (60%) patients were able to void per urethral (p = 0.02). The mean maximum flow rate (Qmax) improved from 8.8 to 11 mls/s and the mean PVR decreased from 200 to 149 mls (p < 0.05). On multivariate analysis, we identified high preoperative PVR, high preoperative actual MUCP, and previous surgical intervention (urethral dilatation, sacral neuromodulation, and pelvic surgery) as predictors of successful voiding restoration. The mean duration of response was 4.7 months, 46% of patients requested repeat injection, and 29% were established on maintenance injections. On the 5-point PGI-I score, 13 (37%), 12 (34%), and 10 (29%) patients reported good, some, and no improvement, respectively. Quality of life was also improved in 60% of patients. Two patients had transient stress urinary incontinence (for <6 weeks) and there were no significant long-lasting adverse events. EUS BTX-A is a valid treatment option for VD considering therapeutic options are limited. The patient must be made aware of the need for repeat treatments.
Substances chimiques
Botulinum Toxins, Type A
EC 3.4.24.69
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1793-1799Informations de copyright
© 2022 Wiley Periodicals LLC.
Références
Kao YL, Huang KH, Kuo HC, Ou YC. The therapeutic effects and pathophysiology of botulinum toxin A on voiding dysfunction due to urethral sphincter dysfunction. Toxins. 2019;11(12):728.
Coyne KS, Sexton CC, Thompson CL, et al. The prevalence of lower urinary tract symptoms (LUTS) in the USA, the UK and Sweden: results from the epidemiology of LUTS (EpiLUTS) study. BJU Int. 2009;104(3):352-360. doi:10.1111/j.1464-410X.2009.08427.x
Robinson D, Staskin D, Laterza RM, Koelbl H. Defining female voiding dysfunction: ICI-RS 2011. Neurourol Urodyn. 2012;31(3):313-316. doi:10.1002/nau.22213
Abdel Raheem A, Madersbacher H. Voiding dysfunction in women: how to manage it correctly. Arab J Urol. 2013;11(4):319-330. doi:10.1016/j.aju.2013.07.005
Nazarko L. Effective evidence-based intermittent self-catheterization: an update. Br J Nurs. 2010;19(18):S4-S6. doi:10.12968/bjon.2010.19.Sup8.79062
Grigoleit U, Pannek J, Stöhrer M. Single-use intermittent catheterisation. Urologe A. 2006;45(2):175-182. doi:10.1007/s00120-006-1007-9
Datta SN, Chaliha C, Singh A, et al. Sacral neurostimulation for urinary retention: 10-year experience from one UK centre. BJU Int. 2008;101(2):192-196. doi:10.1111/j.1464-410X.2007.07282.x
Kessler TM, La Framboise D, Trelle S, et al. Sacral neuromodulation for neurogenic lower urinary tract dysfunction: systematic review and meta-analysis. Eur Urol. 2010;58(6):865-874. doi:10.1016/j.eururo.2010.09.024
Tutolo M, Ammirati E, Heesakkers J, et al. Efficacy and safety of sacral and percutaneous tibial neuromodulation in non-neurogenic lower urinary tract dysfunction and chronic pelvic pain: a systematic review of the literature. Eur Urol. 2018;73(3):406-418. doi:10.1016/j.eururo.2017.11.002
Phelan MW, Franks M, Somogyi GT, et al. Botulinum toxin urethral sphincter injection to restore bladder emptying in men and women with voiding dysfunction. J Urol. 2001;165(4):1107-1110.
Mahfouz W, Karsenty G, Corcos J. Injection of botulinum toxin type A in the urethral sphincter to treat lower urinary tract dysfunction: review of indications, techniques and results: 2011 update. Can J Urol. 2011;18(4):5787-5795.
Lee YK, Kuo HC. Therapeutic effects of botulinum toxin A, via urethral sphincter injection on voiding dysfunction due to different bladder and urethral sphincter dysfunctions. Toxins. 2019;11(9):487. doi:10.3390/toxins11090487
Panicker JN, Seth JH, Khan S, et al. Open-label study evaluating outpatient urethral sphincter injections of onabotulinumtoxin A to treat women with urinary retention due to a primary disorder of sphincter relaxation (Fowler's syndrome). BJU Int. 2016;117(5):809-813. doi:10.1111/bju.13342
Schäfer W, Abrams P, Liao L, et al. Good urodynamic practices: uroflowmetry, filling cystometry, and pressure-flow studies. Neurourol Urodyn. 2002;21(3):261-274. doi:10.1002/nau.10066
Solomon E, Yasmin H, Duffy M, Rashid T, Akinluyi E, Greenwell TJ. Developing and validating a new nomogram for diagnosing bladder outlet obstruction in women. Neurourol Urodyn. 2018;37(1):368-378. doi:10.1002/nau.23307
Brown M, Wickham JE. The urethral pressure profile. Br J Urol. 1969;41(2):211-217. doi:10.1111/j.1464-410x.1969.tb09925.x
Edwards L, Malvern J. The urethral pressure profile: theoretical considerations and clinical application. Br J Urol. 1974;46(3):325-335. doi:10.1111/j.1464-410x.1974.tb03834.x
Lepor H, Machi G. Comparison of AUA symptom index in unselected males and females between fifty-five and seventy-nine years of age. Urology. 1993;42(1):36-40. doi:10.1016/0090-4295(93)90332-5
Okamura K, Nojiri Y, Osuga Y, Tange C. Psychometric analysis of International Prostate Symptom Score for female lower urinary tract symptoms. Urology. 2009;73(6):1199-1202. doi:10.1016/j.urology.2009.01.054
Dykstra DD, Sidi AA. Treatment of detrusor-sphincter dyssynergia with botulinum A toxin: a double-blind study. Arch Phys Med Rehabil. 1990;71(1):24-26.
Kuo HC. Botulinum A toxin urethral injection for the treatment of lower urinary tract dysfunction. J Urol. 2003;170(5):1908-1912. doi:10.1097/01.ju.0000091281.50081.f0
Smith CP, Nishiguchi J, O'Leary M, Yoshimura N, Chancellor MB. Single-institution experience in 110 patients with botulinum toxin A injection into bladder or urethra. Urology. 2005;65(1):37-41. doi:10.1016/j.urology.2004.08.016
Jiang YH, Jhang JF, Chen SF, Kuo HC. Videourodynamic factors predictive of successful onabotulinumtoxin A urethral sphincter injection for neurogenic or non-neurogenic detrusor underactivity. Low Urin Tract Symptoms 2019;11(1):66-71. doi:10.1111/luts.12195
Jiang YH, Wang CC, Kuo HC. Onabotulinumtoxin A urethral sphincter injection as treatment for non-neurogenic voiding dysfunction-a randomized, double-blind, placebo-controlled study. Sci Rep. 2016;6:38905. doi:10.1038/srep38905
Petit H, Wiart L, Gaujard E, et al. Botulinum A toxin treatment for detrusor-sphincter dyssynergia in spinal cord disease. Spinal Cord. 1998;36(2):91-94. doi:10.1038/sj.sc.3100517
‘t Hoen LA, van den Hoek J, Wolffenbuttel KP, van der Toorn F, Scheepe JR. Breaking the vicious circle: onabotulinum toxin A in children with therapy-refractory dysfunctional voiding. J Pediatr Urol. 2015;11(3):119. doi:10.1016/j.jpurol.2014.10.006
Gallien P, Reymann JM, Amarenco G, Nicolas B, de Sèze M, Bellissant E. Placebo controlled, randomised, double blind study of the effects of botulinum A toxin on detrusor sphincter dyssynergia in multiple sclerosis patients. J Neurol Neurosurg Psychiatry. 2005;76(12):1670-1676. doi:10.1136/jnnp.2004.045765
Jiang YH, Chen SF, Jhang JF, Kuo HC. Therapeutic effect of urethral sphincter onabotulinumtoxin A injection for urethral sphincter hyperactivity. Neurourol Urodyn. 2018;37(8):2651-2657. doi:10.1002/nau.23714